Investigational drug · Phase 3
CRN04894
Also called: Atumelnant
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia, Cushing Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
8
Any phase or sponsor naming "CRN04894"
First trial start
2023
Jul 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CRN04894", any sponsor or status.
Conditions studied
As listed on its trial records.
- Congenital Adrenal Hyperplasia
- Classic Congenital Adrenal Hyperplasia
- Cushing Syndrome
- Cushing Disease
- Ectopic ACTH Syndrome
Approved drugs for the same conditions: Cushing's syndrome · Rare and genetic disease · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "CRN04894" as an intervention, largest first.
Crinetics Pharmaceuticals Inc.Industry
NCT06712823 · 200 participants (planned) · Start Feb 25, 2025 · Primary completion Jul 2029
Drug: atumelnant (CRN04894) · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Minneapolis, Minnesota; Morehead City, North Carolina; Philadelphia, Pennsylvania · 13 sites in all
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)Pivotal-lookingRecruiting
Crinetics Pharmaceuticals Inc.Industry
NCT07159841 · 153 participants (planned) · Start Jan 22, 2026 · Primary completion Mar 2030
Drug: Atumelnant; Placebo · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Los Angeles, California; San Francisco, California; Chicago, Illinois · 53 sites in all
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaPivotal-lookingRecruiting
Crinetics Pharmaceuticals Inc.Industry
NCT07144163 · 150 participants (planned) · Start Dec 11, 2025 · Primary completion May 2027
Drug: Atumelnant; Placebo · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Los Angeles, California; Aurora, Colorado; Gainesville, Florida · 82 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT06048887 · 88 participants · Start Dec 18, 2020 · Primary completion Apr 11, 2022
Drug: CRN04894 Oral Solution; Placebo Oral Solution · For: Healthy Volunteers
Sites: Miami, Florida
Crinetics Pharmaceuticals Inc.Industry
NCT07570082 · 46 participants · Start May 28, 2026 · Primary completion Jun 30, 2026
Drug: Atumelnant; Carbamazepine and 3 more · For: Healthy Volunteers
Sites: Lincoln, Nebraska
Crinetics Pharmaceuticals Inc.Industry
NCT05907291 · 38 participants · Start Jul 3, 2023 · Primary completion Aug 22, 2025
Drug: atumelnant (CRN04894) · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Pasadena, California; Ann Arbor, Michigan; Minneapolis, Minnesota · 27 sites in all
Crinetics Pharmaceuticals Inc.Industry
NCT07221084 · 21 participants · Start Oct 28, 2025 · Primary completion Feb 7, 2026
Drug: Atumelnant; Placebo · For: Healthy Volunteers
Sites: Glendale, California
Crinetics Pharmaceuticals Inc.Industry
NCT05804669 · 19 participants · Start Oct 12, 2023 · Primary completion Aug 25, 2026
Drug: atumelnant · For: Cushing Syndrome; Cushing Disease; Ectopic ACTH Syndrome
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- The evolution of new approaches to the treatment of congenital adrenal hyperplasia.
Merke DP, Auchus RJ · Endocr Rev 2026
- Advances in pharmacological treatment for congenital adrenal hyperplasia.
Graves LE, Falhammar H · Curr Opin Pediatr 2026
- Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.
Goai WH, Torpy DJ · Expert Opin Pharmacother 2026
- What is the need for adrenalectomy in patients with congenital adrenal hyperplasia in the era of CRF1/ACTH inhibitors?
Fedorova O, Falhammar H · Front Endocrinol (Lausanne) 2025
- Correction: CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance.
Contreras PH, Falhammar H · Front Endocrinol (Lausanne) 2025
- CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance.
Contreras PH, Falhammar H · Front Endocrinol (Lausanne) 2025
Also in development for Congenital Adrenal Hyperplasia
- Lu AG13909AsedebartPhase 23 trials
H. Lundbeck A/S · Cushing's Disease, Congenital Adrenal Hyperplasia, Adrenal Hyperplasia, Congenital
- NBIP-01435Phase 21 trial
Neurocrine Biosciences · Congenital Adrenal Hyperplasia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.